Inviragen and PharmaJet receive NIH grant for dengue vaccine

10/10/2010 | American City Business Journals

The NIH's National Institute of Allergy and Infectious Diseases has awarded a five-year, $15.5 million grant to Inviragen and PharmaJet to develop a needleless vaccine that can offer protection against all four strains of dengue virus. Inviragen's DENVax vaccine can be administered using PharmaJet's injector that uses pressurized liquid in drug delivery.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX